Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01011 vs Xgeva in Bone Metastases From Solid Tumors
NCT04859569Phase 3Unknown
- Sponsor
- Luye Pharma Group
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of LY01011 in bone metastases (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Natural logarithm change in uNTx/uCr at Week 13. Status: unknown.
02
Drugs
LY01011
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT04859569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859569.